Literature DB >> 27167388

Cytochrome P450 structure-function: insights from molecular dynamics simulations.

Pramod C Nair1,2, Ross A McKinnon2, John O Miners1,2.   

Abstract

Cytochrome P450 (CYP) family 1, 2, and 3 enzymes play an essential role in the metabolic clearance and detoxification of a myriad of structurally and chemically diverse drugs and non-drug xenobiotics. The individual CYP enzymes exhibit distinct substrate and inhibitor selectivities, and hence differing patterns of inhibitory drug-drug interactions. In addition, CYP enzymes differ in terms of regulation of expression, genetic polymorphism, and environmental factors that alter activity. The availability of three-dimensional structures from X-ray crystallography have been invaluable for understanding the structural basis of the ligand selectivity of CYP enzymes. Moreover, the X-ray crystal structures demonstrate that CYP proteins exhibit marked flexibility, particularly around the active site, and the principle of ligand-induced conformational changes is now well accepted. Recent studies have demonstrated that molecular dynamics simulations (MDS) provide an additional approach for modeling the structural flexibility of CYP enzymes, both in the presence and absence of bound ligand, and understanding the functional consequences of plasticity. However, most of the MDS studies reported to date have utilized short simulation time scales, and few have validated the computationally-generated data experimentally (e.g. by site-directed mutagenesis and enzyme kinetic approaches). Although modeling approaches require further development and validation, MDS has the potential to provide a deeper understanding of CYP structure-function than is available from experimental techniques such as X-ray crystallography alone.

Entities:  

Keywords:  Cytochrome P450; access channels; cooperativity; drug–drug interactions; genetic polymorphism; ligand binding; molecular dynamics simulations; plasticity; structure–function

Mesh:

Substances:

Year:  2016        PMID: 27167388     DOI: 10.1080/03602532.2016.1178771

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  19 in total

1.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

2.  Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.

Authors:  Angela Rowland; Madelé van Dyk; David Warncken; Arduino A Mangoni; Michael J Sorich; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

3.  Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.

Authors:  Michael Murray; Tina B Gillani; Tristan Rawling; Pramod C Nair
Journal:  AAPS J       Date:  2019-10-21       Impact factor: 4.009

4.  Substrate mediated redox partner selectivity of cytochrome P450.

Authors:  Katherine A Gentry; Meng Zhang; Sang-Choul Im; Lucy Waskell; Ayyalusamy Ramamoorthy
Journal:  Chem Commun (Camb)       Date:  2018-05-31       Impact factor: 6.222

5.  Spin Interconversion of Heme-Peroxo-Copper Complexes Facilitated by Intramolecular Hydrogen-Bonding Interactions.

Authors:  Andrew W Schaefer; Melanie A Ehudin; David A Quist; Joel A Tang; Kenneth D Karlin; Edward I Solomon
Journal:  J Am Chem Soc       Date:  2019-03-14       Impact factor: 15.419

6.  Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6.

Authors:  Kevin D McCarty; Samuel A Ratliff; Kyle A Furge; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2020-12-29       Impact factor: 3.922

7.  Thermodynamics of camphor migration in cytochrome P450cam by atomistic simulations.

Authors:  J Rydzewski; W Nowak
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

Review 8.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

9.  Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.

Authors:  Clara J Amorosi; Melissa A Chiasson; Matthew G McDonald; Lai Hong Wong; Katherine A Sitko; Gabriel Boyle; John P Kowalski; Allan E Rettie; Douglas M Fowler; Maitreya J Dunham
Journal:  Am J Hum Genet       Date:  2021-07-26       Impact factor: 11.025

10.  Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population.

Authors:  Shabbir Ahmed; Jie Zhou; Zhan Zhou; Shu-Qing Chen
Journal:  Genes (Basel)       Date:  2018-10-22       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.